Tempest Therapeutics rises on partner‑funded plan for new cancer drugs

Tempest Therapeutics

11/02/2026 12:39

** Shares of cancer drug developer Tempest Therapeutics TPST.O rise 2.07% to $2.47 premarket

** Co says it will focus on developing its newly acquired cancer programs, while keeping costs low through partner-funded trials

** Co's TPST-2003, a dual‑targeting CAR‑T for blood cancers, is already being tested in China; larger study expected end-2026 with early data in 2027 – co says

** Co says TPST-4003 aims to treat cancer without complex cell manufacturing, plans to move it into early studies with partner support

** Shares were down ~73% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))